Expert Perspectives on VALIANT: Trial Design and Key Results

Video content above is prompted by the following:

VALIANT Trial – Pegcetacoplan in C3G and Immune Complex MPGN

Study Overview
The VALIANT trial investigated the efficacy and safety of pegcetacoplan, a complement C3 inhibitor, in patients with C3 glomerulopathy (C3G) and immune complex membranoproliferative glomerulonephritis (IC-MPGN). The design included:

• 6-month double-blind phase (pegcetacoplan vs placebo)
• 6-month open-label extension
• Participants: approximately 80% C3G and 20% IC-MPGN
• Included pediatric patients ≥12 years and posttransplant patients

Primary and Secondary End Points

• Primary end point: Reduction in proteinuria at 6 months
• Secondary end points:
  • Change in estimated GFR (eGFR)
  • Histologic response, particularly C3 staining on kidney biopsy

Key Efficacy Findings

• Proteinuria reduction: >65% in pegcetacoplan-treated group
• eGFR preservation: Statistically significant difference vs placebo
• C3 clearance: >70% of patients achieved 0 C3 staining on repeat biopsy
• Posttransplant results: In the NOBLE study (transplants), 50% achieved 0 C3 staining by 12 weeks

Pediatric and Transplant Populations

• Pegcetacoplan showed comparable efficacy across:
  • C3G and IC-MPGN subtypes
  • Adolescents and adults
  • Native and transplant kidneys

Safety Profile

• Pegcetacoplan was well tolerated:
  • No cases of encapsulated Neisseria infections
  • No increase in serious infections (eg, COVID-19, influenza, pneumonia)
  • No major safety signal or treatment arm imbalance
• All participants were appropriately vaccinated against encapsulated bacteria

Clinical Implications

• The trial demonstrated robust control of complement activity, including dramatic histologic responses
• These results support pegcetacoplan as a promising treatment for C3G and IC-MPGN
• Questions remain regarding treatment duration and long-term management, which will require post-approval data

Conclusion

Pegcetacoplan has shown strong efficacy in reducing proteinuria and complement deposition in both native and transplant kidneys across pediatric and adult populations, with a favorable safety profile. These results position pegcetacoplan as a potentially transformative therapy in C3G and IC-MPGN management.